Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 100 participants.

Also called NCT05098470

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose other
Phase
Phase 3
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05098470
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05098470. Randomized; no masking; primary purpose other. Start 2022-03-07 (actual); primary completion 2025-07-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
Intervention (Drug)
Metformin
Intervention (Drug)
Insulin Glargine
Intervention (Drug)
Dorzagliatin
Lead sponsor
University of Alabama at Birmingham (class: other)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct05098470
Content hash
734720d88b3563b691de579e2154ac49f72700b7bbb3f0ad04e562bb0db791ee